Original Article
Copyright ©2010 Baishideng.
World J Gastroenterol. Jul 7, 2010; 16(25): 3133-3143
Published online Jul 7, 2010. doi: 10.3748/wjg.v16.i25.3133
Table 2 Treatment exposure in the safety population
CharacteristicFOLFOX6 plus cetuximab (arm A, n = 77)FOLFIRI plus cetuximab (arm B, n = 74)
Exposure to cetuximab (Q1-Q3)
Median duration, wk28.0 (17-46)29.1 (13-46)
Median number of infusions26.0 (14-40)26.0 (12-42)
Relative dose intensity, n (%)
Only initial dose4 (5)3 (4)
< 60%2 (3)3 (4)
60% to < 80%15 (19)8 (11)
80% to < 90%21 (27)20 (27)
≥ 90%35 (45)40 (54)
Exposure to chemotherapy (Q1-Q3)
Median duration, wk25.1 (19-28)25.5 (14-28)
Median number of cycles12 (7-12)12 (6-12)
Relative dose intensity, n (%)
Oxaliplatin
No dose1 (1)74 (100)
< 60%4 (5)-
60% to < 80%24 (31)-
80% to < 90%22 (29)-
≥ 90%26 (34)-
Irinotecan
No dose77 (100)2 (3)
< 60%-3 (4)
60% to < 80%-18 (24)
80% to < 90%-13 (18)
≥ 90%-38 (51)
Bolus 5-FU
No dose1 (1)2 (3)
< 60%1 (1)2 (3)
60% to < 80%28 (36)19 (26)
80% to < 90%19 (25)14 (19)
≥ 90%28 (36)37 (50)
Continuous infusion 5-FU
No dose1 (1)2 (3)
< 60%1 (1)3 (4)
60% to < 80%21 (27)14 (19)
80% to < 90%13 (17)11 (15)
≥ 90%41 (53)44 (59)
Dose reductions1, n (%)
Cetuximab9 (12)5 (7)
Chemotherapy25 (32)17 (23)
Treatment delays1, n (%)
Any cetuximab
≥ 3 d59 (77)47 (64)
≥ 16 d12 (16)8 (11)
Any chemotherapy
≥ 3 d59 (77)51 (69)
≥ 14 d25 (32)15 (20)
Treatment discontinuation1, n (%)
Cetuximab13 (17)9 (12)
Chemotherapy9 (12)4 (5)

  • Citation: Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16(25): 3133-3143
  • URL: https://www.wjgnet.com/1007-9327/full/v16/i25/3133.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v16.i25.3133